Elicera Therapeutics says USPTO allows U.S. patent application covering ELC-401 CAR-T candidate

• Elicera Therapeutics received a USPTO Notice of Allowance for a U.S. patent application covering its ELC-401 CAR T-cell candidate.
• The application covers anti-IL-13Ra2 antibodies, including use in cancer treatment such as CAR T-cell therapies.
• U.S. exclusivity would support development and commercialization of ELC-401, a CAR T-cell program targeting glioblastoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief via Cision (Ref. ID: 202608280408BITN____UKPR__EN_20260828-BIT-3417-0) on August 28, 2026, and is solely responsible for the information contained therein.